Introduction

Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase; it is effective for the treatment of patients with advanced non-small cell lung cancer (NSCLC). The response rate with gefitinib (250 mg per day) in two randomized double-blind phase II trials of NSCLC patients who failed to respond to platinum-based chemotherapy (IDEAL-1 and IDEAL-2) was 18.4% and 11.8%, respectively
. In the IDEAL-1 study, a higher response rate in Japanese patients compared to non-Japanese patients (28% vs. 10%) was reported. In these studies, disease-related symptoms were also found to be improved with gefitinib monotherapy. Gefitinib is regarded as a relatively safe agent, although toxic effects such as diarrhea and skin rash have been reported (1, 2) . In Japan, gefitinib was approved in July 2002 for the treatment of inoperable or recurrent NSCLC. However, shortly after gefitinib was approved, pulmonary toxicity, including interstitial lung disease (ILD), was reported as a serious, occasionally fatal, adverse effect (3) (4) (5) 
F i g u r e 1 . S e r u m ma r k e r s o f l u n g c a n c e r ( CE A) a n d I L D ( KL -6 , S P -A, a n d S P -D) d u r i n g t h e p at i e n t ' s c l i n i c a l c o u r s e .
F i g u r e 2 . T h i n -s l i c e CT f i n d i n g s b e f o r e ( A) a n d a f t e r ( B ) t h e f i r s t I L D e p i s o d e . T h e s u b p l e u r a l g r o u n d -g l a s s s h a d o ws s e e n b e f o r e t h e f i r s t I L D ( A) we r e t h o u g h t t o b e g r a v i t y -r e l a t e d d e n s i t i e s s i n c e t h o s e s h a d o ws d i s a p p e a r e d i n t h e p r o n e p o s i t i o n ( n o t s h o wn ) . A n e w g r o u n d -g l a s s s h a d o w i s s e e n i n t h e l e f t l o we r l o b e ( B ) .
boplatin and paclitaxel. Therefore, the patient was given gefitinib ( (Fig. 3) . The patient's serum SP-A, SP-D, and KL-6 levels were not elevated at that time (Fig. 1) 
F i g u r e 3 . T h i n -s l i c e CT f i n d i n g s b e f o r e ( A) a n d a f t e r ( B ) t h e s e c o n d I L D e p i s o d e . Ne w g r o u n dg l a s s s h a d o ws a r e s e e n n o t o n l y i n t h e l e f t l o we r l o b e b u t a l s o i n t h e o t h e r l o b e s ( B ) . T h e l e f t ma l i gn a n t p l e u r a l e f f u s i o n wa s n o t s e e n b e f o r e t h e s e c o n d I L D b e c a u s e t h e p l e u r a l f l u i d wa s d r a i n e d t h e r a p e u t i c a l l y j u s t b e f o r e t h e t h i r d c o u r s e o f g e f i t i n i b ( A) .
Discussion
The incidence of gefitinib-related ILD in Japan has been reported to be 4.0%, and in 31.6% of these cases it was fatal (6) 
